Baird Medical Lists in the U.S. on the Nasdaq Exchange
Baird Medical Investment Holdings (NASDAQ: BDMD) has successfully listed on the Nasdaq exchange, marking its transition to a public company. The company, a leading microwave ablation (MWA) medical device developer in China, began trading under the ticker symbol 'BDMD' on October 2, 2024. This milestone follows Baird Medical's recent expansion into the U.S. market after receiving FDA 510(k) clearances.
Co-Founder Wenyuan Wu rang the Opening Bell to celebrate the occasion. The company's technology offers a minimally invasive alternative to thyroidectomy for patients with benign thyroid tumors, addressing a significant market need in the U.S., where 150,000 thyroidectomies are performed annually. Baird Medical's MWA technology aims to provide safer and more efficient procedures for thyroid care, benefiting both patients and physicians.
Baird Medical Investment Holdings (NASDAQ: BDMD) è stata recentemente quotata sulla Borsa Nasdaq, segnando il suo passaggio a società pubblica. L'azienda, un importante sviluppatore di dispositivi medici per ablazione a microonde (MWA) in Cina, ha iniziato a essere scambiata con il simbolo 'BDMD' il 2 ottobre 2024. Questo traguardo segue l'espansione recente di Baird Medical nel mercato statunitense, dopo aver ottenuto le autorizzazioni 510(k) della FDA.
Il co-fondatore Wenyuan Wu ha suonato la campana di apertura per celebrare l'evento. La tecnologia dell'azienda offre un'alternativa minimamente invasiva alla tiroidectomia per i pazienti affetti da tumori benigni della tiroide, affrontando una significativa esigenza di mercato negli Stati Uniti, dove vengono eseguite 150.000 tiroidectomie all'anno. La tecnologia MWA di Baird Medical mira a fornire procedure più sicure ed efficienti per la cura della tiroide, beneficiando sia i pazienti che i medici.
Baird Medical Investment Holdings (NASDAQ: BDMD) ha conseguido listar con éxito en la bolsa Nasdaq, marcando su transición a una empresa pública. La compañía, un desarrollador líder de dispositivos médicos de ablación por microondas (MWA) en China, comenzó a cotizar bajo el símbolo 'BDMD' el 2 de octubre de 2024. Este hito sigue a la reciente expansión de Baird Medical en el mercado estadounidense después de recibir las autorizaciones 510(k) de la FDA.
El cofundador Wenyuan Wu tocó la campana de apertura para celebrar la ocasión. La tecnología de la empresa ofrece una alternativa mínimamente invasiva a la tiroidectomía para pacientes con tumores benignos de tiroides, abordando una necesidad significativa en el mercado estadounidense, donde se realizan 150,000 tiroidectomías anualmente. La tecnología MWA de Baird Medical busca proporcionar procedimientos más seguros y eficientes para el cuidado de la tiroides, beneficiando tanto a pacientes como a médicos.
Baird Medical Investment Holdings (NASDAQ: BDMD)는 나스닥 거래소에 성공적으로 상장되어 공기업으로의 전환을 알렸습니다. 저는 중국의 선도적인 마이크로파 절제(MWA) 의료 기기 개발업체로, 2024년 10월 2일 'BDMD'라는 종목 코드를 사용하여 거래를 시작했습니다. 이 이정표는 Baird Medical이 최근 FDA 510(k) 승인을 받은 후 미국 시장으로 확장한 뒤 이루어진 것입니다.
공동 창립자 Wenyuan Wu는 이 기념일을 축하하기 위해 개장 종을 울렸습니다. 이 회사의 기술은 양성 갑상선 종양이 있는 환자에게 갑상선 절제를 대체할 수 있는 최소 침습적 대안을 제공합니다. 이는 매년 150,000건의 갑상선 절제가 이루어지는 미국 시장의 중요한 필요를 해결하고 있습니다. Baird Medical의 MWA 기술은 더욱 안전하고 효율적인 갑상선 치료 절차를 제공하여 환자와 의사 모두에게 혜택을 주고자 합니다.
Baird Medical Investment Holdings (NASDAQ: BDMD) a réussi à s'inscrire sur la Bourse Nasdaq, marquant ainsi sa transition vers une entreprise publique. L'entreprise, un développeur de dispositifs médicaux d'ablation par micro-ondes (MWA) de premier plan en Chine, a commencé à être échangée sous le symbole 'BDMD' le 2 octobre 2024. Ce jalon fait suite à l'expansion récente de Baird Medical sur le marché américain après avoir obtenu les autorisations 510(k) de la FDA.
Le cofondateur Wenyuan Wu a fait sonner la cloche d'ouverture pour célébrer l'occasion. La technologie de l'entreprise offre une alternative peu invasive à la thyroïdectomie pour les patients présentant des tumeurs bénignes de la thyroïde, répondant à un besoin de marché significatif aux États-Unis, où 150 000 thyroïdectomies sont pratiquées chaque année. La technologie MWA de Baird Medical vise à fournir des procédures plus sûres et plus efficaces pour les soins de la thyroïde, bénéficiant à la fois aux patients et aux médecins.
Baird Medical Investment Holdings (NASDAQ: BDMD) hat erfolgreich an der Nasdaq-Börse notiert, was den Übergang zu einem öffentlichen Unternehmen markiert. Das Unternehmen, ein führender Entwickler von Mikrowellenablation (MWA) medizinischen Geräten in China, begann am 2. Oktober 2024 unter dem Tickersymbol 'BDMD' zu handeln. Dieser Meilenstein folgt auf die jüngste Expansion von Baird Medical auf den US-Markt nach Erhalt der FDA 510(k) Genehmigungen.
Mitbegründer Wenyuan Wu läutete die Eröffnungsglocke zur Feier des Anlasses. Die Technologie des Unternehmens bietet eine minimal-invasive Alternative zur Thyreoidektomie für Patienten mit benignen Schilddrüsentumoren und spricht einen erheblichen Marktbedarf in den USA an, wo jährlich 150.000 Thyreoidektomien durchgeführt werden. Die MWA-Technologie von Baird Medical zielt darauf ab, sicherere und effizientere Verfahren zur Schilddrüsenpflege anzubieten, von denen sowohl Patienten als auch Ärzte profitieren.
- Successful listing on Nasdaq exchange, expanding visibility and potential investor base
- Recent FDA 510(k) clearances for U.S. market entry
- Addressing a significant market need with 150,000 annual thyroidectomies in the U.S.
- Offering minimally invasive alternative to traditional thyroid surgery
- None.
Insights
The listing of Baird Medical on Nasdaq is a significant milestone for the company, marking its transition to a public entity and potentially enhancing its access to capital markets. This move could provide increased liquidity and funding opportunities for future growth and expansion. The company's recent FDA clearance for its microwave ablation technology in the U.S. market is particularly noteworthy, as it opens up a substantial market opportunity with 150,000 annual thyroidectomies performed in the country.
Investors should consider the company's potential for market penetration in the U.S., given its established presence in China and the innovative nature of its technology. However, it's important to note that as a newly listed company, there may be volatility in stock price and historical financial data available for analysis. The success of Baird Medical will likely depend on its ability to effectively commercialize its technology and compete in the U.S. healthcare market.
Baird Medical's microwave ablation (MWA) technology represents a significant advancement in thyroid tumor treatment. The minimally invasive nature of MWA offers potential advantages over traditional thyroidectomy, including reduced recovery time, lower risk of complications and preservation of thyroid function. This aligns with the growing trend towards less invasive medical procedures, which could drive adoption among both physicians and patients.
The market potential is substantial, given the high number of thyroidectomies performed annually in the U.S. However, the company will need to focus on clinical evidence, physician education and reimbursement strategies to ensure widespread adoption. Investors should monitor the company's progress in these areas, as well as any emerging competitive technologies. The success of Baird Medical in the U.S. market could significantly impact its valuation and growth prospects.
Company Rings Opening Bell to Celebrate Closure of Business Combination and Begins Journey as a Public Company; Shares trade under "BDMD" Ticker
"Becoming a public company in
The Nasdaq listing comes as the Company expands its footprint in the U.S. market following recent FDA clearance for its minimally invasive microwave ablation technology, which offers a promising alternative to thyroidectomy for patients with benign thyroid tumors. Currently, 150,000 thyroidectomies are performed in the U.S. annually.
About Baird Medical
Established in 2012 and headquartered in
Contacts
Investor Relations
Robin Yang, Partner
ICR, LLC
Phone: +1 (646) 308-1475
Email: BairdMedical.IR@icrinc.com
Public Relations
Brad Burgess, Senior Vice President
ICR, LLC
Phone: +1 (646) 588-0383
Email: BairdMedical.PR@icrinc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-lists-in-the-us-on-the-nasdaq-exchange-302271491.html
SOURCE Baird Medical Investment Holdings Ltd.
FAQ
When did Baird Medical (BDMD) begin trading on the Nasdaq exchange?
What is Baird Medical's (BDMD) main product or technology?
How many thyroidectomies are performed annually in the U.S. market that Baird Medical (BDMD) is targeting?
What recent regulatory approval did Baird Medical (BDMD) receive for the U.S. market?
